Association Between Cyp2c19 Gene Polymorphisms and Cardiovascular Risk Factors in Patients With Acute Myocardial Infarction

This study aims to investigate CYP2C19 gene polymorphisms and the association between gene polymorphisms with cardiovascular risk factors and major adverse cardiovascular events (MACE) in patients with acute myocardial infarction (AMI). A prospective cross-sectional analysis study involved 86 AMI patients enrolled and assessed CYP2C19 gene polymorphisms with MACE evaluated after three months of AMI treatment. CYP2C19*1*1 genotype accounted for the highest prevalence at 54.7%, which means normal metabolizers phenotype prevalence was the highest. The prevalence of patients with circumflex artery stenting, medical history of taking clopidogrel, percutaneous coronary intervention (PCI), and hypertension in patients with CYP2C19 polymorphism was significantly higher than in those without CYP2C19 polymorphism, 35.9 vs. 10.6, 46.2 vs. 14.9,10.3 vs., and 9.49 vs. 74.5, respectively (p<0.05). In patients with CYP2C19 polymorphisms, using a combination of clopidogrel and aspirin regimen had a 13.6% of cardiovascular mortality, while using ticagrelor and aspirin regimen was 0% (p>0.05). The relationship between CYP2C19 gene polymorphisms and MACE after three months of AMI treatment was not associated. CYP2C19 gene polymorphism is associated with hypertension, medical history of PCI, taking clopidogrel, and circumflex artery stenting injury. This study established the relationship between CYP2C19 gene polymorphism and cardiovascular risk factors in patients with acute myocardial infarction who require testing for this gene polymorphism when suffering from acute myocardial infarction to have a medicine adaptation method. Keywords: Polymorphism, CYP2C19 , Acute Myocardial Infarction, Major Adverse Cardiovascular Events, Percutaneous Coronary Intervention DOI： https://doi.org/10.35741/issn.0258-2724.58.3.11